ArticlePloS one2025
Fermented rice germ extract with high concentration of gamma-aminobutyric acid enhances pentobarbital-induced sleep via GABAergic system in rats.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In modern societies, insomnia stands out as a widespread health concern. Gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, can exert hypnotic effects. However, despite various clinical trials conducted, scientific evidence regarding the impact of ingested GABA on sleep remains unclear. Therefore, in this study, we investigated the sedative effects of fermented rice germ (RG30) extract with a high GABA concentration through electroencephalography (EEG) analysis in a pentobarbital-induced sleep animal model. The exploration into the neural basis of these positive effects involved evaluating orexin, GABAA receptor, and serotonin (5-HT) immunoreactivity in the brain using immunohistochemical methods. Furthermore, we conducted a binding assay for GABAA receptors and 5-HT2C receptors, as these are considered pivotal targets in the mechanism of action for sleep aids. In the binding assay, RG30 displayed binding affinity to the GABAA receptor (IC50 value of 5.911 µg/mL) and 5-HT2C receptor (IC50 value of 56.89 µg/mL). Administration of RG30 increased NREM sleep time and reduced wake time in a pentobarbital-induced sleep model. Low-dose RG30 (RG30_L; 40 mg/kg) induced significant alterations in EEG-defined sleep architecture, whereas high-dose RG30 (RG30_H; 90 mg/kg) predominantly modulated orexin expression in the lateral hypothalamus and GABAA receptor levels in the ventrolateral preoptic nucleus. No significant changes were observed in 5-HT expression within the dorsal raphe nucleus. In conclusion, RG30 increased NREM sleep and significantly improved sleep behavior due to its action on the GABAA receptors. The collective findings suggest that RG30 could be considered as a novel sleep-enhancing agent in pharmaceutical and food industries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.